Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-person">Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris added, "With more than $40 million in cash, including proceeds from our recent $15 million registered direct offering and no debt, combined with our expected significantly reduced burn rate, we are in a solid financial position to execute our focused drug development and business strategy."

CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2010

Revenues were $6.4 million for the three-month period ended March 31, 2010, compared to $6.1 million for the same period in 2009. The increase is mainly due to a comparative increase in sales of Cetrotide(R) to certain customers in the first quarter of 2010. This increase was partly offset by lower amortization of upfront license fee payments in 2010 related to our agreement with sanofi-aventis U.S. LLC ("sanofi-aventis"), which was entered into in March 2009, in connection with our now discontinued development program involving cetrorelix for the treatment of Benign Prostatic Hyperplasia ("BPH"), and subsequently terminated.

Research and development ("R&D") costs, net of tax credits and grants, were $5.7 million for the three-month period ended March 31, 2010, compared to $11.4 million for the same period in 2009. The comparative decrease in net R&D costs is almost entirely attributable to the winding down and termination of development activities related to cetrorelix in BPH, despite the presence in the first quarter of 2010 of residual expenditures associated with certain remaining contractual obligations.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the 1600’s ... known as “The Doctor’s Plague.” In this time period, doctors ... This led, at times, to the death of vulnerable patients. ... don’t know that they may be unwittingly transmitting herpes viruses ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Networks Corporation s recent acquisition of Network Engineering ... brings NEAs strength in the key technology of voice ... announced it bought the Wausau-based IT firm last week ... keep all of NEAs 22 employees. , ,"The combination ...
... interested in achieving greater efficiencies in product development and ... the University of Wisconsin-Madisons Center for Quick Response ... in Biotech briefing, co-hosted by the center and ... held Wednesday, Aug. 18 from 9 a.m. to noon ...
... aimed at protecting businesses , ,MADISON, Wis. ... with MasterCard to help battle online identity ... , ,Under the arrangement, NameProtect will use its technology ... other forms of payment fraud. Phishing describes the act ...
Cached Biology Technology:Berbee acquisition could expand VoIP in Wisconsin 2NameProtect and MasterCard unite to combat online fraud, phishing 2
(Date:4/17/2014)... warning on the possible effects of gases such as ... that of carbon dioxide. Now a team of Swiss-German ... regenerable electron acceptors which helps explain why large amount ... released to the atmosphere. However, there are worries that ... a vicious cycle to release large amounts of methane ...
(Date:4/17/2014)... the genetic information of DNA is used to ... numerous different functions in living organisms. Messenger RNA ... expression, by relating the genetic information of DNA ... , By examining the different types and ... at a given time, researchers can determine which ...
(Date:4/17/2014)... uncovered a new way the immune system may fight ... to use immune cells to treat illness. , The ... immunological equivalent of "neighborhood police" specialized squads of ... instead of an entire city, the body. , Scientists ... have shown that the liver, skin and uterus each ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2
... 19, 2013) Columbia University College of Physicians ... announced that the Mortimer D. Sackler, M.D. Prize ... awarded to Carla Shatz, PhD, the Sapp Family ... Palo Alto, California. Dr. Shatz,s work has advanced ...
... Researchers at Plymouth University, UK, believe that findings from ... between the Early Jurassic era of 180 million years ... Through geology and palaeontology, they,ve shown how higher ... marine communities, and that while the Jurassic seas eventually ...
... elementary school students are expected to attend an INSECT EXPO ... PM on Monday, February 25 at the start of the ... Society of America (ESA), which will be held February 25-28 ... This free educational event will reinforce students, science ...
Cached Biology News:Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 2Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 3Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 4Jurassic records warn of risk to marine life from global warming 2
... 220 utilizes utilizies CTI Molecular Imaging's ... superior resolution, sensitivty, and a large ... the flexibility to image multiple mice ... microPET is a dedicated small animal ...
... I provides a convenient and affordable alternative ... Used with an eight-port disposable manifold, the ... with multi-channel pipettes. The eight-port manifold, designed ... of 100, 200, 250, or 300mL with ...
... Buffered) has been developed specifically for the ... HRP Stabilizer prevents the loss of ... the antibody or protein antigen portion of ... 0.2 microns., ,Contents: Aqueous, protein-containing diluent ...
384 Well PCR Plate Carrier for Thermo-Sealer...
Biology Products: